.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Express Scripts
Fish and Richardson
Deloitte
Harvard Business School
Fuji
Cerilliant
Boehringer Ingelheim
Julphar
Chinese Patent Office

Generated: December 15, 2017

DrugPatentWatch Database Preview

Depomed Inc Company Profile

« Back to Dashboard

What is the competitive landscape for DEPOMED INC, and when can generic versions of DEPOMED INC drugs launch?

DEPOMED INC has eight approved drugs.

There are thirty-six US patents protecting DEPOMED INC drugs.

There are five hundred and eleven patent family members on DEPOMED INC drugs in fifty-one countries and twenty-three supplementary protection certificates in ten countries.

Summary for Depomed Inc

International Patents:511
US Patents:36
Tradenames:7
Ingredients:5
NDAs:8
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Depomed IncNUCYNTA ERtapentadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL200533-003Aug 25, 2011RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Depomed IncNUCYNTAtapentadol hydrochlorideTABLET;ORAL022304-002Nov 20, 2008RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Depomed IncNUCYNTAtapentadol hydrochlorideTABLET;ORAL022304-001Nov 20, 2008RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Depomed IncCAMBIAdiclofenac potassiumFOR SOLUTION;ORAL022165-001Jun 17, 2009ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Depomed IncNUCYNTA ERtapentadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL200533-003Aug 25, 2011RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Depomed IncNUCYNTAtapentadol hydrochlorideSOLUTION;ORAL203794-001Oct 15, 2012RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Depomed IncNUCYNTA ERtapentadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL200533-004Aug 25, 2011RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Depomed IncLAZANDAfentanyl citrateSPRAY, METERED;NASAL022569-002Jun 30, 2011RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Depomed IncCAMBIAdiclofenac potassiumFOR SOLUTION;ORAL022165-001Jun 17, 2009ABRXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Depomed IncGRALISEgabapentinTABLET;ORAL022544-001Jan 28, 2011BXRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Depomed Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Depomed IncPROQUIN XRciprofloxacin hydrochlorideTABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005► Subscribe► Subscribe
Depomed IncNUCYNTAtapentadol hydrochlorideTABLET;ORAL022304-002Nov 20, 2008► Subscribe► Subscribe
Depomed IncCAMBIAdiclofenac potassiumFOR SOLUTION;ORAL022165-001Jun 17, 2009► Subscribe► Subscribe
Depomed IncNUCYNTA ERtapentadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL200533-004Aug 25, 2011► Subscribe► Subscribe
Depomed IncPROQUIN XRciprofloxacin hydrochlorideTABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005► Subscribe► Subscribe
Depomed IncNUCYNTA ERtapentadol hydrochlorideTABLET, EXTENDED RELEASE;ORAL200533-005Aug 25, 2011► Subscribe► Subscribe
Depomed IncGRALISEgabapentinTABLET;ORAL022544-001Jan 28, 2011► Subscribe► Subscribe
Depomed IncGRALISEgabapentinTABLET;ORAL022544-002Jan 28, 2011► Subscribe► Subscribe
Depomed IncNUCYNTAtapentadol hydrochlorideTABLET;ORAL022304-003Nov 20, 2008► Subscribe► Subscribe
Depomed IncPROQUIN XRciprofloxacin hydrochlorideTABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for DEPOMED INC drugs

Drugname Dosage Strength Tradename Submissiondate
tapentadolOral Solution20 mg/mLNUCYNTA12/30/2013
tapentadolOral Solution20 mg/mLNUCYNTA12/20/2013
tapentadol hydrochlorideTabletsx50 mg, 75 mg, and 100 mgNUCYNTA11/20/2012
tapentadol hydrochlorideExtended-release Tablets50 mg, 100 mg, 150 mg, 200 mg, and 250 mgNUCYNTA ER11/20/2012
diclofenac potassiumCapsules25 mgZIPSOR11/14/2012
gabapentinTablets300 mg and 600 mgGRALISE10/31/2011
diclofenacPotassium Oral Solution (Sachet)50 mgCAMBIA1/24/2011

Non-Orange Book Patents for Depomed Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,802,157Methods of treatment using a gastric retained gabapentin dosage form► Subscribe
8,580,303Gastric retained gabapentin dosage form► Subscribe
7,268,166Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases► Subscribe
8,323,889Process for the production of an abuse-proofed solid dosage form► Subscribe
9,629,807Abuse-proofed dosage form► Subscribe
8,475,813Methods of treatment using a gastric retained gabapentin dosage► Subscribe
8,192,722Abuse-proof dosage form► Subscribe
8,114,384Process for the production of an abuse-proofed solid dosage form► Subscribe
8,333,991Gastric retained gabapentin dosage form► Subscribe
6,017,965 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Depomed Inc Drugs

Country Document Number Estimated Expiration
European Patent Office0693475► Subscribe
Portugal1658055► Subscribe
Norway20061055► Subscribe
Lithuania98160► Subscribe
Mexico2013009028► Subscribe
Japan4846552► Subscribe
Argentina045352► Subscribe
Japan2004002437► Subscribe
Peru10872006► Subscribe
Greece3036215► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Depomed Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011007,C0693475Lithuania► SubscribePRODUCT NAME: TAPENTADOLUM; NAT. REGISTRATION NO/DATE: LT/1/10/2341/001 - LT/1/10/2341/66, 2011 02 19; LT/1/10/2342/001 - LT/1/10/2342/110 20110219; FIRST REGISTRATION: 75043.00.00 - 75048.00.00, 2010 08 19; 76261.00.00 - 76270.00.00 20100819
C0016France► SubscribePRODUCT NAME: TAPENTADOL SOUS FORME DE SA BASE LIBRE OU SOUS FORME D'UN DE SES SELS D'ACIDES ACCEPTABLES DU POINT DE VUE PHYSIOLOGIQUE; NAT. REGISTRATION NO/DATE: NL40884 20111003; FIRST REGISTRATION: DE - 76261.00.00 20100819
90004-0.LSweden► SubscribePRODUCT NAME: TAPENTADOL; NAT. REG. NO/DATE: 42622-42628 20100910; FIRST REG.: DE 7543-7548,7661-76270" EESGODKLANDKOD="DE" EESGODKDATUM="2010-08-19" SEGODKNR="42622-42628 20100819
2006000022Germany► SubscribePRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126
C/GB06/022United Kingdom► SubscribePRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124
2010 00036Denmark► SubscribePRODUCT NAME: TAPENTADOL ((1R-2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL), HERUNDER HYDROCHLORIDET; NAT. REG. NO/DATE: 45151-45158, 45162-45169 20100830; FIRST REG. NO/DATE: EU 75043.00.00-75048.00.00, 75261.00.00-75270.00.00 20100819
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
0693475/01Switzerland► SubscribePRODUCT NAME: TAPENTADOL; REGISTRATION NO/DATE: SWISSMEDIC 60530 20110222
793Luxembourg► Subscribe91793, EXPIRES: 20200712
11/010Ireland► SubscribePRODUCT NAME: TAPENTADOL IN BASIC FORM OR IN THE FORM OF A SALT OF A PHYSIOLOGICALLY COMPATIBLE ACID, ESPECIALLY TAPENTADOL HYDROCHLORIDE; NAT REGISTRATION NO/DATE: PA1189/007/001-008 20101221; FIRST REGISTRATION NO/DATE: PA1189/008/001-008 21/12/2010 GERMANY 75043.00.00 75044.00.00 75045.00.00 19/08/2010 GERMANY 76261.00.00 76262.00.00 76263.00.00 76264.00.00 76265.00.00 19/08/2010 GERMANY 75046.00.00 75047.00.00 75048.00.00 19/08/2010 GERMANY 76266.00.00 76267.00.00 76268.00.0076269.00.00 76270.00.00 20100819
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
US Department of Justice
Healthtrust
Queensland Health
Covington
McKesson
Deloitte
Merck
Chubb
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot